Shaw JL, Nielson CM, Park JK, et al. - Researchers used the Flatiron Health Electronic Health Record database to assess thrombocytopenia risk in several malignancies and chemotherapy regimens. Adult patients who underwent chemotherapy for a solid tumor or hematologic cancer from 2012 to 2017 were identified. Experts evaluated 3‐month cumulative incidence of thrombocytopenia by platelet counts, overall, and by grade of thrombocytopenia. Findings revealed variation in the incidence of thrombocytopenia across tumor and regimen types in this large, US‐representative sample of patients receiving chemotherapy in clinical practice. Grade 3 thrombocytopenia occurred in 4% of patients with solid tumors and in 16% with hematologic cancers, in spite of suggestions to modify chemotherapy to avert severe thrombocytopenia. Thrombocytopenia prediction as well as prevention may aid oncologists in averting dose modifications as well as its adverse impacts on survival.